HRGN 8-K
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 14, 2020
BIOSTAGE, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35853 | 45-5210462 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 84 October Hill Road, Suite 11, Holliston, MA | 01746 |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (774) 233-7300
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
| Item 2.02. | Results of Operations and Financial Condition. |
On May 14, 2020, Biostage, Inc., or the Company, issued a press release announcing financial results for the three months ended March 31, 2020. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number |
Title | |
| 99.1 | Press Release issued by Biostage, Inc. on May 14, 2020 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIOSTAGE, INC. | ||
| (Registrant) | ||
| May 14, 2020 | /s/ Hong Yu | |
| (Date) | Hong Yu | |
| President |
EXHIBIT 99.1
Biostage Reports First Quarter 2020 Financial Results
Holliston, MA – May 14, 2020 – Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company’s novel Cellspan™ technology, today announced its financial results for the three months ended March 31, 2020.
The Company will not hold an earnings conference call at this time. The Company plans to hold a conference call at a future date to discuss its clinical and business plans based on the U.S. Food and Drug Administration (FDA) removing the clinical hold on its Cellspan Esophageal Implant (CEI) study.
Operating Highlights
On March 19, 2020, the FDA notified the Company that the clinical hold on its CEI product candidate has been removed and the Company may proceed with its First in Human (FIH) Clinical study. This FDA approval enables us to start clinical planning, including engaging with a clinical research organization and site readiness in advance of starting the clinical trial for our CEI product candidate. The COVID-19 pandemic has and will continue to affect the Company’s operations, including causing delays or difficulties in its ability to plan and commence clinical trials.
Summary of Financial Results
For the three months ended March 31, 2020, the Company reported a net loss of $2.0 million, ($0.24) per share, compared to a net loss of $1.9 million, ($0.32) per share, for the three months ended March 31, 2019. The $0.1 million year-over-year increase in net loss was due primarily to a $0.3 million increase in general and administrative expenses costs, a $0.1 million decrease in grant income for qualified expenditures from our Fast-Track Small Business Innovation Research grant, and a $0.1 million increase in expense due to the change in the fair value of our warrant liability. This was offset, in part, by a $0.4 million decrease in research and development costs.
Balance Sheet and Cash
At March 31, 2020, the Company had operating cash on-hand of $0.8 million and no debt. The Company used net cash in operations of $1.1 million during the three-month period ended March 31, 2020.
During the three months ended March 31, 2020, the Company received $1.0 million from financing activities, including approximately $0.6 million from the issuance of 151,027 shares of common stock and warrants to investors in private placement transactions, and approximately $0.4 million from the issuance of 214,000 shares of its common stock to a group of investors in connection with the exercise of previously issued warrants.
About Biostage, Inc.
Biostage is a clinical-stage biotechnology company developing bioengineered organ implants based on the Company’s novel Cellspan™ technology. The Company’s Cellspan technology combines a proprietary, biocompatible scaffold with a patient’s own cells to create an esophageal implant that could potentially be used to treat pediatric esophageal atresia and other tubular organ conditions. Our novel technology harnesses the body’s response and modulates it toward the healing process to regenerate tissue and restore the continuity and integrity of the organ. These implants have the potential to dramatically improve the quality of life for children and adults. At Biostage, we believe the future of medicine has been inside us all along.
For more information, please visit www.biostage.com and connect with the Company on Twitter and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the viability of our technology; success with respect to any clinical trials and other development and commercialization efforts of the Company’s products, which such success may not be achieved on a timely basis or at all; our financing activities; expectations as to regulatory approval of any of the Company’s products, including those utilizing its Cellspan™ and Cellframe™ technology, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which approvals may not be obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the Company’s inability to obtain needed funds in the immediate future; the impact of COVID-19 on our business and operations; the Company’s ability to obtain and maintain regulatory approval for its products; plus other factors described under the heading "Item 1A. Risk Factors" in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 or described in the Company’s other public filings. The Company’s results may also be affected by factors of which the Company is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
Investor Relations Contacts
Shunfu Hu
Vice President of Business Development and Operations
774-233-7300
Peter Chakoutis
Vice President of Finance
774-233-7300
BIOSTAGE, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value and share data)
March 31, 2020 | December 31, 2019 | |||||||
| ASSETS | (Unaudited) | |||||||
| Current assets: | ||||||||
| Cash | $ | 806 | $ | 913 | ||||
| Restricted cash | 50 | 50 | ||||||
| Prepaid expenses and other current assets | 346 | 444 | ||||||
| Total current assets | 1,202 | 1,407 | ||||||
| Property, plant and equipment, net | 346 | 394 | ||||||
| Right-of-use assets | 166 | 191 | ||||||
| Total non-current assets | 512 | 585 | ||||||
| Total assets | $ | 1,714 | $ | 1,992 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 227 | $ | 241 | ||||
| Accrued and other current liabilities | 544 | 438 | ||||||
| Warrant liability | 133 | 33 | ||||||
| Current portion of operating lease liability | 105 | 102 | ||||||
| Total current liabilities | 1,009 | 814 | ||||||
| Operating lease liability, net of current portion | 61 | 89 | ||||||
| Total liabilities | $ | 1,070 | $ | 903 | ||||
| Stockholders’ equity: | ||||||||
| Undesignated preferred stock, $0.01 par value; 984,000 shares authorized and none issued and outstanding at March 31, 2020 and December 31, 2019 | $ | - | $ | - | ||||
| Common stock, par value $0.01 per share, 60,000,000 shares authorized at March 31, 2020 and December 31, 2019; 8,532,532 and 8,155,555 issued and outstanding at March 31, 2020 and December 31, 2019, respectively | 85 | 82 | ||||||
| Additional paid-in capital | 66,650 | 65,102 | ||||||
| Accumulated deficit | (66,091 | ) | (64,095 | ) | ||||
| Total stockholders’ equity | 644 | 1,089 | ||||||
| Total liabilities and stockholders’ equity | $ | 1,714 | $ | 1,992 | ||||
BIOSTAGE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share amounts)
Three Months ended March 31, | ||||||||
| 2020 | 2019 | |||||||
| Revenues | $ | - | $ | - | ||||
| Operating expenses: | ||||||||
| Research and development | 643 | 1,034 | ||||||
| Selling, general and administrative | 1,253 | 1,000 | ||||||
| Total operating expenses | 1,896 | 2,034 | ||||||
| Operating loss | (1,896 | ) | (2,034 | ) | ||||
| Other income (expense): | ||||||||
| Grant income | - | 114 | ||||||
| Change in fair value of warrant liability | (100 | ) | (7 | ) | ||||
| Total other income (expense), net | (100 | ) | 107 | |||||
| Net loss | $ | (1,996 | ) | $ | (1,927 | ) | ||
| Basic and diluted net loss per share | $ | (0.24 | ) | $ | (0.32 | ) | ||
| Weighted average common shares, basic and diluted | 8,287 | 6,003 | ||||||
BIOSTAGE, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
Three Months Ended March 31, | ||||||||
| 2020 | 2019 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net loss | $ | (1,996 | ) | $ | (1,927 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Share-based compensation expense | 588 | 293 | ||||||
| Depreciation | 48 | 61 | ||||||
| Amortization of right-of-use assets | 25 | 23 | ||||||
| Change in fair value of warrant liability | 100 | 7 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Grant receivable | - | 62 | ||||||
| Prepaid expenses and other current assets | 98 | 124 | ||||||
| Accounts payable | (14 | ) | 127 | |||||
| Accrued and other current liabilities | 82 | 37 | ||||||
| Lease liabilities | (25 | ) | (23 | |||||
| Net cash used in operating activities | (1,094 | ) | (1,216 | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Purchases of property, plant and equipment | - | (24 | ||||||
| Net cash used in investing activities | - | (24 | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Proceeds from issuance of common stock and warrants, net of offering costs | 559 | - | ||||||
| Proceeds from exercise of warrants | 428 | 1,000 | ||||||
| Net cash provided by financing activities | 987 | 1,000 | ||||||
| Net decrease in cash and restricted cash | (107 | ) | (240 | ) | ||||
| Cash and restricted cash at the beginning of the year | 963 | 1,355 | ||||||
| Cash and restricted cash at the end of the year | $ | 856 | $ | 1,115 | ||||